OncoSynergy Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $250K
Latest Deal Amount
  • Investors
  • 17

OncoSynergy General Information

Description

Developer of oncology therapeutics designed to improve outcomes for patients with unmet needs in oncology. The company's therapeutics include RMIs (Resistance Mechanism Inhibitors) that features multiple simultaneous mechanisms of action and synergy, thereby enabling oncologists to treat hematological cancers with ease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 850 Pacific Street
  • Unit 1802
  • Stamford, CT 06902
  • United States
+1 (415) 000-0000

OncoSynergy Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSynergy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 24-Nov-2020 $250K 000.00 Completed Clinical Trials - Phase 1
7. Seed Round 08-Sep-2020 00.000 000.00 Completed Clinical Trials - Phase 1
6. Grant 24-Jan-2020 00000 0000 Completed Clinical Trials - General
5. Seed Round 14-May-2018 0000 0000 0000 Completed Clinical Trials - General
4. Accelerator/Incubator 19-May-2017 Completed Clinical Trials - General
3. Accelerator/Incubator Completed Clinical Trials - General
2. Merger/Acquisition 05-Apr-2016 Cancelled Clinical Trials - General
1. Equity Crowdfunding 28-Jun-2015 $13.2M Completed Clinical Trials - General
To view OncoSynergy’s complete valuation and funding history, request access »

OncoSynergy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OncoSynergy’s complete cap table history, request access »

OncoSynergy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of oncology therapeutics designed to improve outcomes for patients with unmet needs in oncology. The company's
Drug Discovery
Stamford, CT
7 As of 2020
000.00
0000000000 0 000.00

000000 0

im ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000

00000000

re magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000 000000000
Schlieren, Switzerland
0 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoSynergy Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
000000000 Venture Capital-Backed Schlieren, Switzerland 0 000.00 00000000000 000.00
000000000 00000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000000 00000
000000000000000 Venture Capital-Backed Saint Louis, MO 0 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
You’re viewing 5 of 42 competitors. Get the full list »

OncoSynergy Executive Team (4)

Name Title Board Seat Contact Info
Anne-Marie Carbonell MD Co-Founder, Chief Executive Officer, President, Chief Medical Officer and Board Member
Ambar Picon Vice President, Corporate Operations
Greg Wilson Consulting Chief Financial Officer
To view OncoSynergy’s complete executive team members history, request access »

OncoSynergy Board Members (5)

Name Representing Role Since
Allen Salmasi Ph.D Self Chairman 000 0000
Amanda Hayward Ph.D Connecticut Innovations Board Member 000 0000
Colin Foster Self Board Member 000 0000
Hen Park Ph.D OncoSynergy Board Member 000 0000
Robert Dunkle OncoSynergy Board Member 000 0000
To view OncoSynergy’s complete board members history, request access »

OncoSynergy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoSynergy Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Cancer Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Korea Information & Communications Company Corporation Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

OncoSynergy Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 01-May-2013 000000000000000000 Pharmaceuticals
To view OncoSynergy’s complete acquisitions history, request access »